Exeter-based university spin-out Senisca Ltd has added £3.7m seed money to a £1.1m not dilutive funding to advance its pipeline of drugs targetting RNA splicing dysregulation.
Despite the recent stock market rally and declining volatility, IPOs are rather rare in many industrialised countries –not least for seasonal reasons. The main reason for this, however, is the aggressive monetary policy of the central banks, with more than ten interest rate hikes in both Europe and the US.
Radiopharmaceutical Therapy (RPT) is offering several advantages over existing therapeutic strategies. The highly sought-after therapeutics require a sophisticated supply chain, as radioisotopes have short half-lives and must be delivered to patients with extreme speed and efficiency. ITM rises to this challenge as one of the largest global providers and developers of medical radioisotopes for this novel therapy.
The biotech and pharma branch is growing steadily. Many companies have full order books for the next few years and expect growth. This is the basis for new investments in assets and infrastructure. These growing structures often expose vulnerabilities and challenges for the business. Therefore, companies need to increase the stability and efficiency of their processes.
French endocrine diseases specialist Amolyt Pharma SA has entered into a take-over agreement by AstraZeneca.
London-based virtual drug discovery specialist Relation Therapeutics Ltd has closed another US$35m seed financing round, bringing its total seed fundraise to US$60m.
TREM2, a receptor on the surface of macrophages, reduces necrotic core formation in early atherosclerosis, a German-Austrian reseach team reports.
As cultivated meat moves closer to commercialisation, we are seeing a worrying trend of misinformation entering the public debate. This food can play a vital role in ensuring Europe’s food system is fit for the future – helping satisfy the growing demand for meat while boosting food security – but political opposition has mounted, with the Italian government taking the controversial step of banning cultivated meat.
The world of microbial product manufacturing is a complex landscape, driven by a diverse range of molecule formats and manufacturing processes. At the forefront of this specialty market is Boehringer Ingelheim Vienna, one global leader in biopharmaceutical development and manufacturing.
In times of the pandemic it was called to ban patents that are related to Covid-19 vaccines, medicaments, and diagnostics and the European Parliament was in favour of it. Now there is a call from the European Parliament to ban all patents on new genomics techniques (NTG) and plants. Quo vadis?